PTGS1 and migraine disorder: Therefore, over time, the targets 5-HT1B/D (triptans) and cyclooxygenase-1 (COX1) (NSAIDs) will be gradually abandoned since CGRP, whose use in migraine prevention has not shown particular AEs or tachyphylaxis, as reported in randomized controlled trials.